# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

A. 510(k) Number: k051185   
B. Purpose for Submission: New device   
C. Measurand: Quality Control Material (assayed for CA 19-9)   
D. Type of Test: Calibration Verification Material for CA 19-9   
E. Applicant: Roche Diagnostics Corp.   
F. Proprietary and Established Names: Elecsys $\textsuperscript { \textregistered }$ CA 19-9 CalCheck™

# G. Regulatory Information:

1. Regulation section: 21 CFR §862.1660 Quality control material (assayed and unassayed)   
2. Classification: Class I   
3. Product code: JJX   
4. Panel: 75 – Clinical Chemistry

# H. Intended Use:

Intended use:   
Elecsys $\textsuperscript { \textregistered }$ CA 19-9 Cal Check™ is intended for use in the verification of the calibration established by the Elecsys $\textsuperscript { \textregistered }$ CA 19-9 reagent on the Elecsys $\textsuperscript { \textregistered }$ 1010/2010/MODULAR E170 immunoassay analyzers.   
2. Indications for use: Same as intended use.   
3. Special conditions for use statement(s): None.   
4. Special instrument requirements: Elecsys $\textsuperscript { \textregistered }$ 1010, 2010 andMODULAR ANALYTICS E170

# I. Device Description:

The Elecsys $\textsuperscript { \textregistered }$ CA 19-9 CalCheck™ is a lyophilized product consisting of CA 19-9 in a buffered human serum matrix. During manufacture, the analytes are spiked into the matrix at the desired concentrations.

# J. Substantial Equivalence Information:

1. Predicate device name: Elecsys $\textsuperscript { \textregistered }$ C-Peptide CalCheck™   
2. Predicate 510(k) number: k040157   
3. Comparison with predicate:

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Characteristic</td><td rowspan=1 colspan=1>Elecsys CA 19-9CalCheck</td><td rowspan=1 colspan=1>Predicate deviceElecsys C-PeptideCalCheck</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Elecsys? CA 19-9 CalCheckTM is intended foruse in the verification ofthe calibration establishedby the Elecsys® CA 19-9reagent on the Elecsys?1010/2010/MODULARE170 immunoassayanalyzers</td><td rowspan=1 colspan=1>Elecsys? C-PeptideCalCheckTM is intendedfor use in the verificationof the calibrationestablished by theElecsys? C-Peptidereagent on the Elecsys?immunoassay systems.</td></tr><tr><td rowspan=1 colspan=1>Levels</td><td rowspan=1 colspan=1>Three</td><td rowspan=1 colspan=1>same</td></tr><tr><td rowspan=1 colspan=1>Format</td><td rowspan=1 colspan=1>Lyophilized</td><td rowspan=1 colspan=1>same</td></tr><tr><td rowspan=1 colspan=1>Handling</td><td rowspan=1 colspan=1>Reconstitute with exactly1.0 mL distilled ordeionized water andallow standing closed for15 minutes, then mixinggently.</td><td rowspan=1 colspan=1> same</td></tr><tr><td rowspan=1 colspan=1>Stability</td><td rowspan=1 colspan=1>Unopened:Store at 2 - 8C untilexpiration dateReconstituted:20 - 25℃: 4 hours</td><td rowspan=1 colspan=1>same</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Characteristic</td><td rowspan=1 colspan=1>Elecsys CA 19-9CalCheck</td><td rowspan=1 colspan=1>Predicate deviceElecsys C-PeptideCalCheck</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>Human serum with addedhuman CA 19-9</td><td rowspan=1 colspan=1>Buffered horse serumwith added C-Peptide</td></tr></table>

K. Standard/Guidance Document Referenced (if applicable): None referenced.

L. Test Principle: Not applicable

M. Performance Characteristics (if/when applicable):

1. Analytical performance: a. Precision/Reproducibility: Not applicable. b. Linearity/assay reportable range: Not applicable. c. Traceability, Stability, Expected values (controls, calibrators, or methods): Traceability: - There is no reference material for CA 19-9. The values for the CA 19-9 master calibrators are calibrated against Enzymun Test CA 19-9.

Values are assigned using four Elecsys $\textsuperscript { \textregistered }$ MODULAR ANALYTICS E170 Immunoassay Analyzers, four ELECSYS $\textsuperscript { \textregistered }$ 2010 Immunoassay Analyzers and four ELECSYS $\textsuperscript { \textregistered }$ 1010 Immunoassay Analyzers. Two independent series of analyses are performed on each instrument. Each sample is tested in duplicate. The target value is then calculated as the median of the determined values. Approximate target values are found in the following table. Lotspecific target values may differ slightly after value assignment.

<table><tr><td rowspan=1 colspan=1>CA19-9 CalCheckTM Level</td><td rowspan=1 colspan=1>CA 19-9 Target ValuesIU/mL</td></tr><tr><td rowspan=1 colspan=1>Check 1 (low)</td><td rowspan=1 colspan=1>&lt;5</td></tr><tr><td rowspan=1 colspan=1>Check 2 (medium)</td><td rowspan=1 colspan=1>179</td></tr><tr><td rowspan=1 colspan=1>Check 3 (high)</td><td rowspan=1 colspan=1>676</td></tr></table>

Stability: Two studies were performed in order to verify the stability claims for the Elecsys $\textsuperscript { \textregistered }$ CA 19-9 CalCheck™.

<table><tr><td rowspan=1 colspan=1>Stability</td><td rowspan=1 colspan=1>Unopened</td><td rowspan=1 colspan=1>Reconstituted</td></tr><tr><td rowspan=1 colspan=1>CA 19-9CalCheckTM</td><td rowspan=1 colspan=1>Store at 2 - 8℃untilexpiration date</td><td rowspan=1 colspan=1>20 -25℃: 4 hrs</td></tr></table>

Study 1: Accelerated Stability. The CA 19-9 CalCheck™ on-test material was stored at $3 5 ^ { \circ } \mathrm { C }$ for 3 weeks. At the end of three weeks, it was analyzed in duplicate with a reference material (master calibrators stored at $4 { - } 8 ^ { \circ } \mathrm { C } )$ . The product met the acceptance criterion $( 9 0 \% - 1 1 0 \%$ of the reference value). The sponsor will test for real-time stability.

Study 2: Reconstituted Material: Stability of the reconstituted product and reconstituted reference material are tested in duplicate. The product is reconstituted, stored for four hours at $2 5 ^ { \circ } \mathrm { C }$ . The reference is a freshly reconstituted set of CA 19-9 CalCheck materials. The product met the stated acceptance criterion $( 9 0 \% - 1 1 0 \%$ of the reference value) to support the stability claim of 4 hours at $2 0 { - } 2 5 ^ { \circ } \mathrm { C }$ .

Expected Values: Representative Assigned Values of One Lot of Product

<table><tr><td rowspan=1 colspan=1>Level</td><td rowspan=1 colspan=1>Value</td><td rowspan=1 colspan=1>Range</td><td rowspan=1 colspan=1>Unit</td></tr><tr><td rowspan=1 colspan=1>Check1</td><td rowspan=1 colspan=1>&gt;5</td><td rowspan=1 colspan=1>&lt;5</td><td rowspan=1 colspan=1>U/M1</td></tr><tr><td rowspan=1 colspan=1>Check2</td><td rowspan=1 colspan=1>158</td><td rowspan=1 colspan=1>125-191</td><td rowspan=1 colspan=1>U/mL</td></tr><tr><td rowspan=1 colspan=1>Check3</td><td rowspan=1 colspan=1>617</td><td rowspan=1 colspan=1>487-747</td><td rowspan=1 colspan=1>U/mL</td></tr></table>

d. Detection limit: Not applicable.

e. Analytical specificity: Not applicable.   
$f .$ Assay cut-off: Not applicable.

2. Comparison studies: a. Method comparison with predicate device: Not applicable. b. Matrix comparison: Not applicable.

3. Clinical studies: a. Clinical Sensitivity: Not applicable. b. Clinical specificity: Not applicable. c. Other clinical supportive data (when a. and b. are not applicable): Not applicable.

4. Clinical cut-off: Not applicable

5. Expected values/Reference range: See section 1c which describes the expected values for the product.

N. Proposed Labeling: The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10

# O. Conclusion:

The submitted information in this premarket notification is complete and supports substantial equivalence decision.